Fuchs E F, Horton D, Weckerle W, Winter-Mihaly E
J Med Chem. 1979 Apr;22(4):406-11. doi: 10.1021/jm00190a010.
Daunorubicin analogues in which the natural amino sugar, daunosamine, is replaced by neutral 2,6-dideoxy-hexopyranosyl residues have been prepared in high yields. Glycosidation of 3,4-di-O-acetyl-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl chloride (13) with daunomycinone under Koenigs-Knorr conditions yielded exclusively the protected alpha-anomeric product 4, which was converted into the free glycoside 5. In contrast, the 1-chloro-D-ribo isomer 19, bearing p-nitrobenzoyl groups for hydroxyl-group protection, furnished a 5:3 mixture of the alpha (6) and beta (7) glycosides. Separation and individual deprotection afforded the target compounds 8 (from 6) and 9 (from 7). Whereas all of the D-ribo analogues (6--9) are inactive as antitumor agents in vivo against P388 lymphocytic leukemia in mice, the protected L-lyxo glycoside 4 (T/C 186) and also the free glycoside 5 (T/C 183) are highly effective in this test system; 5 is also active (T/C 146) in vivo against murine B16 melanocarcinoma.
已高产率制备了柔红霉素类似物,其中天然氨基糖柔红糖胺被中性2,6 - 二脱氧 - 己吡喃糖基残基取代。在柯尼希斯 - 克诺尔条件下,3,4 - 二 - O - 乙酰基 - 2,6 - 二脱氧 - α - L - 来苏 - 己吡喃糖基氯(13)与柔红霉素酮进行糖苷化反应,仅生成受保护的α - 异头物产物4,其被转化为游离糖苷5。相比之下,带有对硝基苯甲酰基用于羟基保护的1 - 氯 - D - 核糖异构体19,得到α(6)和β(7)糖苷的5:3混合物。分离并分别脱保护得到目标化合物8(来自6)和9(来自7)。虽然所有D - ribo类似物(6 - 9)在体内对小鼠P388淋巴细胞白血病无抗肿瘤活性,但受保护的L - 来苏糖苷4(T/C 186)以及游离糖苷5(T/C 183)在该测试系统中非常有效;5在体内对小鼠B16黑色素瘤也有活性(T/C 146)。